# EXL01 listing is produced correctly

    Code
      result
    Output
      Listing of Exposure to Study Drug
      
      ————————————————————————————————————————————————————————————————————————————————————————————————————————
                                                 Study Day   Study Day                                        
      Treatment   Center/Subject ID    Visit       From         To       Dose   Unit   Frequency      Route   
      ————————————————————————————————————————————————————————————————————————————————————————————————————————
       Placebo        701/1015        BASELINE       1          15        0      mg       QD       TRANSDERMAL
                                       WEEK 2       16          168       0      mg       QD       TRANSDERMAL
                                      WEEK 24       169         182       0      mg       QD       TRANSDERMAL
                      701/1023        BASELINE       1          23        0      mg       QD       TRANSDERMAL
                                       WEEK 2       24          28        0      mg       QD       TRANSDERMAL
                      701/1047        BASELINE       1          14        0      mg       QD       TRANSDERMAL
                                       WEEK 2       15          26        0      mg       QD       TRANSDERMAL
                      701/1118        BASELINE       1          15        0      mg       QD       TRANSDERMAL
                                       WEEK 2       16          169       0      mg       QD       TRANSDERMAL
                                      WEEK 24       170         182       0      mg       QD       TRANSDERMAL
                      701/1130        BASELINE       1          15        0      mg       QD       TRANSDERMAL
                                       WEEK 2       16          169       0      mg       QD       TRANSDERMAL
                                      WEEK 24       170         183       0      mg       QD       TRANSDERMAL
                      701/1153        BASELINE       1          16        0      mg       QD       TRANSDERMAL
                                       WEEK 2       17          170       0      mg       QD       TRANSDERMAL
                                      WEEK 24       171         175       0      mg       QD       TRANSDERMAL
                      701/1203        BASELINE       1          22        0      mg       QD       TRANSDERMAL
                                       WEEK 2       23          171       0      mg       QD       TRANSDERMAL
                                      WEEK 24       172         183       0      mg       QD       TRANSDERMAL
                      701/1234        BASELINE       1          23        0      mg       QD       TRANSDERMAL
                                       WEEK 2       24          165       0      mg       QD       TRANSDERMAL
                                      WEEK 24       166         177       0      mg       QD       TRANSDERMAL
                      701/1345        BASELINE       1          17        0      mg       QD       TRANSDERMAL
                                       WEEK 2       18          162       0      mg       QD       TRANSDERMAL
                      701/1363        BASELINE       1          14        0      mg       QD       TRANSDERMAL
                                       WEEK 2       15          168       0      mg       QD       TRANSDERMAL
                                      WEEK 24       169         182       0      mg       QD       TRANSDERMAL
                      701/1387        BASELINE       1          14        0      mg       QD       TRANSDERMAL
                      701/1392        BASELINE       1          15        0      mg       QD       TRANSDERMAL
                                       WEEK 2       16          170       0      mg       QD       TRANSDERMAL
                                      WEEK 24       171         183       0      mg       QD       TRANSDERMAL
                      701/1415        BASELINE       1          15        0      mg       QD       TRANSDERMAL
                                       WEEK 2       16          169       0      mg       QD       TRANSDERMAL
                                      WEEK 24       170         183       0      mg       QD       TRANSDERMAL
                      701/1440        BASELINE       1          16        0      mg       QD       TRANSDERMAL
                                       WEEK 2       17          168       0      mg       QD       TRANSDERMAL
                                      WEEK 24       169         182       0      mg       QD       TRANSDERMAL
                      703/1042        BASELINE       1          13        0      mg       QD       TRANSDERMAL
                                       WEEK 2       14          161       0      mg       QD       TRANSDERMAL
                                      WEEK 24       162         183       0      mg       QD       TRANSDERMAL
                      703/1096        BASELINE       1          16        0      mg       QD       TRANSDERMAL
                                       WEEK 2       17          51        0      mg       QD       TRANSDERMAL
                      703/1100        BASELINE       1          17        0      mg       QD       TRANSDERMAL
                                       WEEK 2       18          169       0      mg       QD       TRANSDERMAL
                                      WEEK 24       170         186       0      mg       QD       TRANSDERMAL
                      703/1175        BASELINE       1           7        0      mg       QD       TRANSDERMAL
                      703/1210        BASELINE       1          15        0      mg       QD       TRANSDERMAL
                                       WEEK 2       16          162       0      mg       QD       TRANSDERMAL
                                      WEEK 24       163         175       0      mg       QD       TRANSDERMAL
                      703/1299        BASELINE       1          17        0      mg       QD       TRANSDERMAL

